Midwest Cardiovascular Research Foundation Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2011
NCT01345188
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Midwest Cardiovascular Research Foundation

Active Ingredients

Drugs in Phase 4 Trials (1)

ranolazine (ranexa) (1 trial)

Drugs in Other Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 4)

Chest Pain (Phase 4)

Dyspnea (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2